Slide 1: Half Year Report to 30th September 2022
Half Year Report to 30th September 2022 Harnessing The Power of Sulforaphane December 2022
Slide 2: Important notice and disclaimer
THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA
Slide 3: Evgen - A Clinical Stage Drug Development Company
Evgen - A Clinical Stage Drug Development Company Focus on breast cancer, glioma and other cancers. SFX-01 has three molecular targets; STAT 3, Nrf2 and SHP2 • Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas
Slide 4: Our Pipeline
Our Pipeline Discovery Pre Phase 1 Phase 2 Phase 3 Breast Cancer The Christie Neurodevelopmental Disorders \ Q) STALICLA Glioblastoma Haematological Malignancies OXFORD Junta de Andalucia onside Analogues uy CSIC A
Slide 5: Half Year Highlights
Half Year Highlights Regulatory UK Regulatory Authority MHRA approval for PK/PD Healthy Volunteer Study Manufacturing Scale-up of the active ingredient in SFX-01 to GMP standards and commercial scale achieved with a number of process improvements New EC Tabs New formulation of SFX-01 manufactured to
Slide 6: Post Period End
Post Period End Transformative Out-licensing deal for SFX-01 in neurodevelopmental disorders and Transaction schizophrenia with STALICLA SA Milestones of $160.5m, double digit royalty Netherlands Positive scientific advice regarding the SFX-01 programme in glioblastoma Regulatory (GBM) Authority (ME
Slide 7: Financials; six months to 30 September 2022
Financials; six months to 30 September 2022 P&L Post tax loss of £2.1m (2021: loss of £1.5m) Cash flow Cash outflow from operations of £1.9m (2021: outflow of £1.5m) Period end cash Cash and short-term deposits at 30 September 2022 of £7.2m (30 September 2021: position £10.1m) Cash runway Into Q4 20
Slide 8: Outlook
Outlook Phase 1 PK/PD PK/PD data expected before H2/2023 Study Prep for Supporting STALICLA’s IND submission in H2 2023 STALICLA ASD Phase II trial GBM Additional pre-clinical work and prep for early-stage ISS 2023 News Results of pre-clinical collaborations in mBC, GBM, flow colorectal cancer and r
Slide 9: Management and Board
Management and Board Dr Huw Jones Richard Moulson Barry Clare CEO CFO Chairman Over 30 years’ experience of Qualified chartered accountant with Former main Board member of Boots leadership in public and private R&D- over 20 years experience working as a Company plc and Chairman UHSM based companies
Slide 10: Evgen Pharma Plc enquiries
Evgen Pharma Plc enquiries@evgen.com www.evgen.com